Rambam Medical Center
Haifa, 31096, Israel
NCT Number: NCT00192725
Serotonin (5-HT) is important in mood regulation and is believed to play a major role in the pathophysiology of major depression (MD). Selective serotonin reuptake inhibitors (SSRIs) are currently the most widely used drugs for the treatment of depression. Patients with bipolar disorder (BD) who are treated for depression with SSRIs might develop mania, which is believed to be triggered by antidepressant treatment. Rapid tryptophan depletion (RTD) has been shown to induce transient depressive symptoms in remitted depressed patients treated with SSRIs. In remitted manic patients treated with lithium, RTD does not seem to have clinical effects. However, RTD was not studied in acutely manic patients and could theoretically have antimanic properties. In this double blind randomized placebo controlled study RTD will be used as a tool to assess the role of 5-HT in mania and will be evaluated for its antimanic properties and potential use as augmentation to drug treatment in acute mania.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Haifa, 31096, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Amino-acid mixture without tryptophan
Time frame: Before and after intervention
Time frame: Before and after intervention
Looking for future studies?
Notify MeRambam Health Care Campus
Other
Tryptophan Depletion in Acute Mania - A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001174
Anxiety Disorders, Behavior
Bethesda, Maryland, United States
View Trial DetailsNCT01876524
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Cartagena, Murcia, Spain
View Trial DetailsNCT04202393
Bipolar Disorder, Bipolar and Related Disorders
Providence, Rhode Island, United States
View Trial DetailsNCT05064319
Bipolar Disorder, Bipolar I Disorder
Charleston, South Carolina, United States
View Trial Details